Table 6 Study design and results for five studies investigating COVID-19 mortality in patients with cancer infected with SARS-Cov-2

From: Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Data CCC19 (ref. 9) UK Coronavirus Cancer Monitoring Project13 Gustave Roussy cohort TERAVOLT10 Curie cohort34
Patients with cancer (n) 928 800 178 200 76
Cancer population All cancers All cancers All cancers Thoracic cancer Breast cancer
Multicentric Yes Yes No Yes No
Median follow-up 21 d Not specified 23 d 15 d Not specified
Primary endpoint All-cause mortality within 30 d of diagnosis of COVID-19 All-cause mortality All-cause mortality and clinical worsening-free survival All-cause mortality Death or ICU admission
Inclusion of biological findings No No Yes No Yes
Inclusion of CT findings No No Yes No Yes
Inclusion of type of cancer systemic treatment used (delay before COVID-19) Yes (1 month) Yes (1 month) Yes (3 months) Yes (not specified) Yes (1 month)
Inclusion of COVID-19 systemic treatment used Yes No Yes No Yes
Inclusion of impact on cancer treatment strategy after COVID-19 diagnosis No No Yes No No
Prognostic factors of death studied in univariable analysis Increased age (per 10 years), male sex, smoking status (former smoker versus never smoked), number of comorbidities (two versus none), type of malignancy (multiple cancers versus only solid tumor), active cancer (progressing versus remission), ECOG score ≥2 and azithromycin/hydroxychloroquine treatment Age, male sex, hypertension, cardiovascular disease, COVID-19 severity score, ICU admission and shortness of breath Age ≥70 years, smoking status (current and former), ECOG score ≥2 at last follow-up, onco-hematological status (metastatic disease), use of cytotoxic chemotherapy in past 3 months and levels of CRP, procalcitonin, lymphopenia, monocytopenia, ferritin, LDH, albumin and troponin Age >65 years, smoking status (current versus former smoker), treatment with chemotherapy, presence of any comorbidities and dyspnea Age (>70 years) and hypertensiona
Prognostic factors of death studied in multivariate analysis Increased age (OR = 1.84; 95% CI = 1.53–2.21), male sex (OR = 1.63; 95% CI = 1.07–2.48), smoking status (OR = 1.60; 95% CI = 1.03–2.47), number of comorbidities (2 versus 0) (OR = 4.50; 95% = 1.33–15.28), ECOG score ≥2 (OR = 3.89; 95% CI = 2.11–7.18), active cancer (progressing versus remission) (OR = 5.20; 95% CI = 2.77–9.77) and azithromycin/hydroxychloroquine treatment (OR = 2.93; 95% CI = 1.79–4.79) Noneb ECOG score at last follow-up ≥2 (HR = 5.83; 95% CI = 2.60–13.1), CRP levels (HR = 2.80; 95% CI = 1.01–7.78) and D-dimer levels (HR = 2.63; 95% CI = 1.15–6.01) Smoking history (OR = 3.18; 95% CI = 1.11–9.06) Not done
  1. aDeath or ICU admission.
  2. bMultivariable analysis was only done for cancer treatment. There was no significant effect on mortality for patients who received chemotherapy in the past 4 weeks, immunotherapy, hormonal therapy, targeted therapy, or radiotherapy in the past 4 weeks.
  3. CT, computed tomography; OR, odds ratio.